Papers/PMID:24830937
Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.
Archives of medical research2014The record
5 findings · 1 compound · 5 endpoints
What it reported
How to read these marksWhat moved
5 findings
magnesium(2+) — decreases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.”
Quoted verbatim from Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Dose
- 30 mL of MgCl2 5% solution (382 mg magnesium) once daily for 4 months
- Population
- Metabolically obese, normal-weight adults with hypomagnesemia; MgCl2 solution versus placebo solution
Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.2014PMID:24830937Permalink
magnesium(2+) — decreases HOMA-IR
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×4“At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.”
Quoted verbatim from Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Dose
- 30 mL of MgCl2 5% solution (382 mg magnesium) once daily for 4 months
- Population
- Metabolically obese, normal-weight adults with hypomagnesemia; MgCl2 solution versus placebo solution
Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.2014PMID:24830937Permalink
magnesium(2+) — decreases fasting blood glucose
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×11“At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.”
Quoted verbatim from Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Dose
- 30 mL of MgCl2 5% solution (382 mg magnesium) once daily for 4 months
- Population
- Metabolically obese, normal-weight adults with hypomagnesemia; MgCl2 solution versus placebo solution
Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.2014PMID:24830937Permalink
magnesium(2+) — decreases diastolic blood pressure (setting unspecified)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×5“At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.”
Quoted verbatim from Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Dose
- 30 mL of MgCl2 5% solution (382 mg magnesium) once daily for 4 months
- Population
- Metabolically obese, normal-weight adults with hypomagnesemia; MgCl2 solution versus placebo solution
Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.2014PMID:24830937Permalink
magnesium(2+) — decreases systolic blood pressure (setting unspecified)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×5“At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.”
Quoted verbatim from Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Dose
- 30 mL of MgCl2 5% solution (382 mg magnesium) once daily for 4 months
- Population
- Metabolically obese, normal-weight adults with hypomagnesemia; MgCl2 solution versus placebo solution
Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.2014PMID:24830937Permalink